Drug Trial Radar · NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
187
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Aug 1, 2028
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
BMS-986393Drug
Specified dose on specified days
AlnuctamabDrug
Specified dose on specified days
MezigdomideDrug
Specified dose on specified days
IberdomideDrug
Specified dose on specified days
ElranatamabDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to 2 years
- Incidence of serious adverse events (SAEs)Time frame: Up to 2 years
- Incidence of adverse events of special interest (AESI)Time frame: Up to 2 years
- Incidence of AEs leading to discontinuationTime frame: Up to 2 years
- Number of DeathsTime frame: Up to 2 years
- Establish recommended Phase 2 dose (RP2D)Time frame: Up to 2 years
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Northside Hospital
Atlanta, Georgia · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota · Recruiting
University Of Nebraska Medical Center
Omaha, Nebraska · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center
New York, New York · Recruiting
Local Institution - 0009
New York, New York · Completed
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Local Institution - 0023
Pittsburgh, Pennsylvania · Withdrawn
Tennessee Oncology
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.